42% of people over 55 are expected to develop dementia, yet new anti-amyloid drugs show limited benefit. A recent study identifies 16 modifiable factors like Lyme disease, mold exposure, and infections that might slow cognitive decline when addressed alongside medication.
42% of people 55 years or older expected to become demented. That is mind-numbing that we would even remotely accept that. And yet they spend $2.4 billion a year at the NIH and no one has come up with a solution for it. So this article that I just published where there's 16 factors now gives people hope. It's like, hold on, I have cognitive decline, I have Alzheimer's, but there's things now that give people hope. Like, I don't just have to go on an anti-amyloid antibody like lecanemab, donanemab, which they just showed in a Cochrane review is really not making much difference. Now, maybe if you addressed the infections like Lyme and Bartonella and pulled out the mold and addressed all these other inflammatory factors, these drugs might actually be more effective. And that's something— and I know looking at these chronic diseases, God bless him, because we needed someone to take a look at this.
